Blood Products Advisory Committee
This article was originally published in The Gray Sheet
Executive Summary
Meeting March 25-26 in Bethesda, Maryland. On March 25, the committee is scheduled to review a product license application for a peptide based assay for antibody to hepatitis C virus and discuss donor screening for HTLV-II. On March 26, the committee will review two draft memoranda: "Revised Recommendations for Testing for Antibody to Anti-HCV" and "Licensing Requirements for Irradiated Blood Products." The committee also is scheduled to discuss extending the indications for intravenous immune globulin. Contact person is Linda Smallwood at (301) 227- 6700.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.